3 questions hanging over the Novo-Catalent deal

To keep up with intense demand for its GLP-1 drugs Wegovy and Ozempic, Danish drug maker Novo Nordisk has brokered an uncommon deal with Catalent, a New Jersey-based contract manufacturer, which has at least one competitor and a regulator on alert.3 questions hanging over the Novo-Catalent deal